CD19 and acute lymphoblastic leukemia: On 30th August 2017 the United States Food and Drug Administration (FDA) approved the use of tisagenlecleucel (CTL019), a CD19-directed CAR T-cell product, for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.